A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

Prospective Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna Test (Assay) in the Management of Early-stage Breast Cancers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02395575

Enrollment

200

Registered

2015-03-23

Start date

2015-03-31

Completion date

2017-10-31

Last updated

2017-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The primary objective of this study is to evaluate the impact of the result of the Prosigna Test (assay) on the therapeutic decision of adjuvant therapy (chemotherapy and hormone therapy) in patients suffering from early-stage breast cancer.

Detailed description

The secondary objectives will consist of: * The evaluation of the confidence in the therapeutic indications of the practitioners before and after the test (assay) results, and by subgroups of cancers * The evaluation of the rate of secondary effects of chemotherapy, * The evaluation of the emotional state of patients faced with the therapeutic decision, of their degree of anxiety and of their functional status before and after the Prosigna test (assay) results

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0) * Estrogen receptor status will be evaluated by Immunohistochemistry (IHC) and more than 1% of stained tumor cells will be considered positive. * HER2 status will be evaluated by IHC (0 or 1+, or 2+ will be considered negative) and by in-situ fluorescence hybridization. * Postmenopausal women defined as: * Natural Amenorrhea \> 12 months, regardless of age * Bilateral oophorectomy, regardless of age (the oophorectomy must have been carried out at least 4 weeks before entering the study) * Radiological castration with amenorrhea \> 3 months, regardless of age * Hysterectomy and postmenopausal blood levels * Able to give consent * Eligible for treatment of breast cancer with adjuvant chemotherapy * ECOG performance status of 0 or 1

Exclusion criteria

* Tumor size T3-T4 * Non-invasive breast cancer (e.g., Paget's disease, DCIS) * Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+) * Tumors that are estrogen-receptor negative or HER2 positive * Have metastatic disease * Unable to give informed consent * Unable to complete patient reported outcome surveys * Have contraindications for adjuvant chemotherapy * Age, performance status, significant comorbidities * ECOG performance status \> 1

Design outcomes

Primary

Measure	Time frame
The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test results.	6 months

Countries

France

Outcome results